Evaluations & learnings

Evaluations provide independent assessments of our work, help us make adjustments and plan for the future.

Our evaluation framework is based on the internationally accepted evaluation framework of the Organization for Economic Co-operation and Development’s Development Assistance Committee, including its principles and criteria for grant evaluations. The framework was updated in 2022 to align with our 2023-2027 Strategy.

We require at least one evaluation for each investment or portfolio of investments, typically conducted within 12 months of closure. We also conduct prospective evaluations to facilitate real-time learning and thematic evaluations to review performance and capture learning within cross-cutting areas of our strategic framework.

Upcoming evaluations

There are no current evaluations planned. Check back regularly for updates.

November 2011

Mid-term evaluation: MDR-TB Scale-Up Initiative 2007-2012, MDR-TB Acceleration of Access Initiative, Strategic Rotating Stockpile, First-Line Anti-TB Drugs Initiative

Evaluation report

August 2011

Mid-term evaluation: EXPAND-TB project

Evaluation report

April 2011

Mid-term evaluation: Assured artemisinin supply system

Evaluation report

April 2011

Mid-term evaluation: WHO prequalification programme

Evaluation report

September 2007

End-of-project evaluation: WHO assessment of Unitaid supply of Artemisinin-based Combination Therapies (ACTs) to Burundi and Liberia

Evaluation report
1 6 7 8